Terminated × Mycosis Fungoides × Dermatologic × Clear all
NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Stanford University

Phase 1 Terminated
3 enrolled 5 charts
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT00726830 2020-09-24

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase NA Terminated
1 enrolled 3 charts
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT00651716 2019-11-15

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Vanderbilt-Ingram Cancer Center

Terminated
150 enrolled
NCT01159067 2019-06-18

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

City of Hope Medical Center

Phase 2 Terminated
1 enrolled 4 charts
NCT01408043 2019-06-14

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase NA Terminated
25 enrolled 15 charts
NCT00290706 2019-05-28

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Northwestern University

Phase 1/2 Terminated
32 enrolled 12 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT00949052 2018-08-16

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Vanderbilt-Ingram Cancer Center

Terminated
1,000 enrolled
NCT00290628 2017-11-29

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
43 enrolled
NCT01419795 2017-07-27

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
NCT01076270 2017-06-28

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase NA Terminated
1 enrolled 7 charts
NCT00324324 2017-05-09

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

OHSU Knight Cancer Institute

Phase 3 Terminated
240 enrolled
NCT00900068 2017-05-09

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

OHSU Knight Cancer Institute

Terminated
9 enrolled
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT00946283 2017-02-03

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Rutgers, The State University of New Jersey

Phase NA Terminated
30 enrolled
NCT00255684 2016-11-03

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

University of Rochester

Phase NA Terminated
16 enrolled 6 charts
NCT00112723 2016-08-08

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled 12 charts
NCT00004239 2016-07-04

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Alliance for Clinical Trials in Oncology

Phase 1 Terminated
10 enrolled
NCT00800150 2015-06-08

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

City of Hope Medical Center

Phase 1 Terminated
6 enrolled
NCT00952185 2015-06-08

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

City of Hope Medical Center

Phase NA Terminated
9 enrolled
NCT01077440 2014-12-10

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

Vanderbilt University

Terminated
24 enrolled
NCT00008216 2014-06-06

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Columbia University

Terminated
48 enrolled
NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
NCT00996359 2013-09-17

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Rutgers, The State University of New Jersey

Phase 1 Terminated
4 enrolled
NCT00504205 2013-08-02

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase NA Terminated
30 enrolled
NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled